Lineage Cell Therapeutics’ (LCTX) Buy Rating Reiterated at HC Wainwright

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports.

Several other equities analysts have also recently weighed in on the stock. D. Boral Capital reiterated a “buy” rating and set a $3.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday, May 4th. B. Riley Financial boosted their target price on shares of Lineage Cell Therapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Finally, Canaccord Genuity Group started coverage on Lineage Cell Therapeutics in a report on Tuesday, April 28th. They issued a “buy” rating and a $9.00 target price for the company. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $6.25.

Lineage Cell Therapeutics Price Performance

Shares of LCTX opened at $1.22 on Tuesday. The company has a 50-day moving average of $1.28 and a two-hundred day moving average of $1.52. The stock has a market cap of $304.15 million, a price-to-earnings ratio of -4.21 and a beta of 1.51. Lineage Cell Therapeutics has a one year low of $0.93 and a one year high of $2.09.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). The firm had revenue of $1.73 million for the quarter, compared to analyst estimates of $3.60 million. Lineage Cell Therapeutics had a negative net margin of 434.44% and a negative return on equity of 89.36%. Analysts anticipate that Lineage Cell Therapeutics will post -0.07 earnings per share for the current year.

Institutional Trading of Lineage Cell Therapeutics

A number of hedge funds have recently made changes to their positions in LCTX. SG Americas Securities LLC purchased a new stake in shares of Lineage Cell Therapeutics in the fourth quarter worth approximately $25,000. Jump Financial LLC purchased a new position in Lineage Cell Therapeutics during the second quarter valued at approximately $28,000. DLD Asset Management LP acquired a new position in Lineage Cell Therapeutics in the 4th quarter valued at approximately $33,000. Define Financial LLC acquired a new position in Lineage Cell Therapeutics in the 4th quarter valued at approximately $33,000. Finally, Qube Research & Technologies Ltd acquired a new position in Lineage Cell Therapeutics in the 2nd quarter valued at approximately $35,000. 62.47% of the stock is owned by hedge funds and other institutional investors.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.